✦ LIBER ✦

Evaluation of Potential Molecular Markers for Urban Stormwater Runoff

✍ Scribed by Eddy Y. Zeng; Kim Tran; Diana Young

Book ID: 111580980
Publisher: Springer
Year: 2004
Tongue: English
Weight: 212 KB
Volume: 90
Category: Article
ISSN: 0167-6369
DOI: 10.1023/b:emas.0000003564.24169.86

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

HYDROLOGIC DESIGN CONSIDERATIONS OF CONS

HYDROLOGIC DESIGN CONSIDERATIONS OF CONSTRUCTED WETLANDS FOR URBAN STORMWATER RUNOFF

✍ Tonja Koob; Michael E. Barber; Wade E. Hathhorn 📂 Article 📅 1999 🏛 American Water Resources Association 🌐 English ⚖ 170 KB

Evaluation of First Flush for Indicator

Evaluation of First Flush for Indicator Bacteria and Total Suspended Solids in Urban Stormwater Runoff

✍ Jon M. Hathaway; William F. Hunt 📂 Article 📅 2010 🏛 Springer Netherlands 🌐 English ⚖ 676 KB

Potential of Aquatic Macrophytes as Bioi

Potential of Aquatic Macrophytes as Bioindicators of Heavy Metal Pollution in Urban Stormwater Runoff

✍ Séverine Ladislas; Amelène El-Mufleh; Claire Gérente; Florent Chazarenc; Yves An 📂 Article 📅 2011 🏛 Springer Netherlands 🌐 English ⚖ 524 KB

The potential value of mosses for stormw

The potential value of mosses for stormwater management in urban environments

✍ Malcolm Anderson; John Lambrinos; Erin Schroll 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 232 KB

The use of benthic invertebrate data for

The use of benthic invertebrate data for evaluating impacts of urban runoff

✍ E. R. Pedersen; M. A. Perkins 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 742 KB

Meta-analysis for the evaluation of pote

Meta-analysis for the evaluation of potential surrogate markers

✍ Michael J. Daniels; Michael D. Hughes 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB 👁 2 views

We describe a meta-analysis approach for the evaluation of a potential surrogate marker. Surrogate markers are useful in helping to identify therapeutic mechanisms of action and disease pathogenesis, and for selecting therapies to take forward from phase II to phase III clinical trials. They have al